CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) — the same signal your hypothalamus uses to tell your pituitary to produce growth hormone. Ipamorelin is a selective ghrelin receptor agonist that amplifies GH pulses through a completely separate receptor pathway.

Used together, researchers describe this as dual-pathway GH stimulation — CJC-1295 drives GH synthesis while ipamorelin increases the size of each GH pulse. What distinguishes ipamorelin from older GHRPs is its selectivity: it stimulates GH release without meaningfully raising cortisol or prolactin.

Published human data confirms CJC-1295 produces sustained GH and IGF-1 elevation while preserving the natural pulsatile pattern of GH secretion — a key physiological advantage over exogenous GH.